Valuation dashboard for Biomea Fusion, Inc. (BMEA) with P/E N/A, P/B 12.54, EV/EBITDA -3.30 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; an...
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $1.74, BMEA has negative trailing earnings (P/E not meaningful) and an ROE of -171.19%. Market capitalisation stands at $126M.
Balance sheet quality for BMEA: current ratio of 5.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 12.54 |
| EV / EBITDA | -3.30 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.98 |
| vs Current Price | -43.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BMEA | Biomea Fusion, Inc. | $126M | 12.54 | -171.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.74 |
| Market Cap | $126M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -171.19% |
| Return on Invested Capital | -212.95% |
| Return on Assets | -88.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · CAMP · CBUS · GUTS · IMUX · PMVP
Explore sector: Healthcare · Biotechnology
More sections of BMEA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks